NewAmsterdam Pharma Company N.V. NAMS 深 滬
已收盤 02-06 16:00:00 美东时间
34.30
+2.240
+6.99%
華盛通- 最 高34.74
- 今 開32.78
- 成交量 53.71万股
- 最 低 32.15
- 昨 收 32.06
- 總市值 38.89亿
- 52周最高 42.00
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 14.06
- 委 比 92.02%
- 總股本 1.13亿
- 歷史最高 42.00
- 量 比 0.78
- 振 幅 8.08%
- 歷史最低 5.6326
- 每 手 1
- 風險率 7.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $47
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.
01-21 22:43
NewAmsterdam Pharma Issues Update On Obicetrapib Clinical Development Program And Outlines Strategic Priorities For 2026; EMA Approval Decision On Obicetrapib Anticipated In 2H26
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY ---- First patient
01-09 21:07
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
New Amsterdam Pharma provided updates on obicetrapib's clinical development, targeting LDL-C lowering for CVD patients. They expect EMA approval in 2H26 and reported PREVAIL CVOT data aligning with BROADWAY trial results. The RUBENS trial, assessing obicetrapib in metabolic syndrome patients, enrolled its first patients. Financially, they ended 2025 with $729M in cash, supporting future trials and potential U.S. launch. Strategic priorities inclu...
01-09 13:00
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.
2025-12-17 01:28
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.
2025-12-03 02:14
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.
2025-11-07 00:22
